Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes

Cindy K. Bahler, Cheryl R. Hann, Michael P Fautsch, Douglas H. Johnson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

PURPOSE. To determine the effect of disruption of Schlemm's canal cells on outflow facility. Pharmacologic agents that weaken the cytoskeleton or interfere with integrin binding may allow targeted disruption of the cells lining Schlemm's canal because of the transmural pressure gradient the cells face as aqueous passes into the canal. METHODS. Anterior segments of human eyes were placed in perfusion organ culture, and either single or sequential doses of H-7 or RGD peptide were added. Fellow eyes received vehicle or RGE peptide. Eyes were fixed and examined by light and electron microscopy. RESULTS. Both agents caused a partial loss of the endothelial lining of Schlemm's canal cells without disruption of trabecular cells in other regions. H-7 significantly increased outflow facility after single or sequential doses, with moderate cell loss of both the inner and outer wall canal cells: 20.0% ± 10.5% of the width of the canal versus 5.2% ± 3.7% in control meshworks (P = 0.05). No significant correlation between the amount of canal cell loss and outflow facility was found. RGD was associated with a variable loss of canal cells but did not change outflow facility. CONCLUSIONS. Pharmacologic disruption of Schlemm's canal cells appears possible. H-7 increased outflow facility, causing a partial loss of the endothelial lining of Schlemm's canal. A simple relationship between canal cells and outflow facility was not found; canal cells probably interact with the extracellular matrix in influencing outflow facility.

Original languageEnglish (US)
Pages (from-to)2246-2254
Number of pages9
JournalInvestigative Ophthalmology and Visual Science
Volume45
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Anterior Eye Segment
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
arginyl-glycyl-glutamic acid
Organ Culture Techniques
Cytoskeleton
Integrins
Cell Wall
Extracellular Matrix
Electron Microscopy
Perfusion

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes. / Bahler, Cindy K.; Hann, Cheryl R.; Fautsch, Michael P; Johnson, Douglas H.

In: Investigative Ophthalmology and Visual Science, Vol. 45, No. 7, 07.2004, p. 2246-2254.

Research output: Contribution to journalArticle

@article{05269965a41b45b1a0cb72033ca88785,
title = "Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes",
abstract = "PURPOSE. To determine the effect of disruption of Schlemm's canal cells on outflow facility. Pharmacologic agents that weaken the cytoskeleton or interfere with integrin binding may allow targeted disruption of the cells lining Schlemm's canal because of the transmural pressure gradient the cells face as aqueous passes into the canal. METHODS. Anterior segments of human eyes were placed in perfusion organ culture, and either single or sequential doses of H-7 or RGD peptide were added. Fellow eyes received vehicle or RGE peptide. Eyes were fixed and examined by light and electron microscopy. RESULTS. Both agents caused a partial loss of the endothelial lining of Schlemm's canal cells without disruption of trabecular cells in other regions. H-7 significantly increased outflow facility after single or sequential doses, with moderate cell loss of both the inner and outer wall canal cells: 20.0{\%} ± 10.5{\%} of the width of the canal versus 5.2{\%} ± 3.7{\%} in control meshworks (P = 0.05). No significant correlation between the amount of canal cell loss and outflow facility was found. RGD was associated with a variable loss of canal cells but did not change outflow facility. CONCLUSIONS. Pharmacologic disruption of Schlemm's canal cells appears possible. H-7 increased outflow facility, causing a partial loss of the endothelial lining of Schlemm's canal. A simple relationship between canal cells and outflow facility was not found; canal cells probably interact with the extracellular matrix in influencing outflow facility.",
author = "Bahler, {Cindy K.} and Hann, {Cheryl R.} and Fautsch, {Michael P} and Johnson, {Douglas H.}",
year = "2004",
month = "7",
doi = "10.1167/iovs.03-0746",
language = "English (US)",
volume = "45",
pages = "2246--2254",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes

AU - Bahler, Cindy K.

AU - Hann, Cheryl R.

AU - Fautsch, Michael P

AU - Johnson, Douglas H.

PY - 2004/7

Y1 - 2004/7

N2 - PURPOSE. To determine the effect of disruption of Schlemm's canal cells on outflow facility. Pharmacologic agents that weaken the cytoskeleton or interfere with integrin binding may allow targeted disruption of the cells lining Schlemm's canal because of the transmural pressure gradient the cells face as aqueous passes into the canal. METHODS. Anterior segments of human eyes were placed in perfusion organ culture, and either single or sequential doses of H-7 or RGD peptide were added. Fellow eyes received vehicle or RGE peptide. Eyes were fixed and examined by light and electron microscopy. RESULTS. Both agents caused a partial loss of the endothelial lining of Schlemm's canal cells without disruption of trabecular cells in other regions. H-7 significantly increased outflow facility after single or sequential doses, with moderate cell loss of both the inner and outer wall canal cells: 20.0% ± 10.5% of the width of the canal versus 5.2% ± 3.7% in control meshworks (P = 0.05). No significant correlation between the amount of canal cell loss and outflow facility was found. RGD was associated with a variable loss of canal cells but did not change outflow facility. CONCLUSIONS. Pharmacologic disruption of Schlemm's canal cells appears possible. H-7 increased outflow facility, causing a partial loss of the endothelial lining of Schlemm's canal. A simple relationship between canal cells and outflow facility was not found; canal cells probably interact with the extracellular matrix in influencing outflow facility.

AB - PURPOSE. To determine the effect of disruption of Schlemm's canal cells on outflow facility. Pharmacologic agents that weaken the cytoskeleton or interfere with integrin binding may allow targeted disruption of the cells lining Schlemm's canal because of the transmural pressure gradient the cells face as aqueous passes into the canal. METHODS. Anterior segments of human eyes were placed in perfusion organ culture, and either single or sequential doses of H-7 or RGD peptide were added. Fellow eyes received vehicle or RGE peptide. Eyes were fixed and examined by light and electron microscopy. RESULTS. Both agents caused a partial loss of the endothelial lining of Schlemm's canal cells without disruption of trabecular cells in other regions. H-7 significantly increased outflow facility after single or sequential doses, with moderate cell loss of both the inner and outer wall canal cells: 20.0% ± 10.5% of the width of the canal versus 5.2% ± 3.7% in control meshworks (P = 0.05). No significant correlation between the amount of canal cell loss and outflow facility was found. RGD was associated with a variable loss of canal cells but did not change outflow facility. CONCLUSIONS. Pharmacologic disruption of Schlemm's canal cells appears possible. H-7 increased outflow facility, causing a partial loss of the endothelial lining of Schlemm's canal. A simple relationship between canal cells and outflow facility was not found; canal cells probably interact with the extracellular matrix in influencing outflow facility.

UR - http://www.scopus.com/inward/record.url?scp=3142651360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142651360&partnerID=8YFLogxK

U2 - 10.1167/iovs.03-0746

DO - 10.1167/iovs.03-0746

M3 - Article

C2 - 15223802

AN - SCOPUS:3142651360

VL - 45

SP - 2246

EP - 2254

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 7

ER -